- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Roxana Siles: Blinded Trials Are Important When Evaluating Chronic Cough Treatment
Roxana Siles, MD, FAAAAI, staff in the Department of Allergy and Immunology at Cleveland Clinic and codirector of the Asthma Center at Cleveland Clinic, addresses the placebo effect seen in clinical trials of chronic cough treatment.
Roxana Siles, MD, FAAAAI, staff in the Department of Allergy and Immunology at Cleveland Clinic and codirector of the Asthma Center at Cleveland Clinic, addresses why a placebo effect is often seen in clinical trials investigating the impact of chronic cough treatment and how this is addressed.
Transcript
How might the placebo effect impact in clinical trials for chronic cough treatment be overcome when testing a medication’s effectiveness?
The placebo effect is real, and it’s not uncommon for patients who enter clinical trials for treatment of cough that they go through rigorous evaluation and they really maximize the therapy. One thing that’s common in trials is that patients tend to be perhaps more adherent to the regimen because they are in trials and perhaps they’re being monitored more closely. So yes, it can be tricky. But certainly, this is why we have blinded, placebo-controlled [trials], because they will tell us whether or not an effective treatment despite having that placebo benefit is even that much more effective when it comes to statistical data and finding that it is a good comparison.
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Data Back Neoadjuvant Combo vs Chemo Alone for Early-Stage NSCLC
April 24th 2024For patients with early-stage non–small cell lung cancer (NSCLC), combining neoadjuvant immune checkpoint inhibitors and platinum-based chemotherapy improves 2-year outcomes over chemotherapy alone, suggest findings of an extensive literature review and meta-analysis.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Polatuzumab Vedotin and R-CHP Appropriate for Untreated DLBCL
April 24th 2024Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).
Read More
